Covered recipient · General Payments record
KONSTANTINOS DAMIRIS
General Payments · PY2022–2024
$1,285.27
- Reported across 28 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $722.87 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $213.06 | 5 |
| Medtronic, Inc. | $200.99 | 5 |
| BOSTON SCIENTIFIC CORPORATION | $130.27 | 3 |
| Gilead Sciences, Inc. | $124.02 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.43 | 1 |
| Ardelyx, Inc. | $20.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.34 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103597004 | CMS |
| ABBVIE INC. | $27.19 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103597006 | CMS |
| ABBVIE INC. | $0.98 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103597008 | CMS |
| ABBVIE INC. | $11.69 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103597010 | CMS |
| ABBVIE INC. | $148.86 | 10/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103597012 | CMS |
| Ardelyx, Inc. | $20.10 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146677054 | CMS |
| Boston Scientific Corporation | $85.82 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092313109 | CMS |
| Boston Scientific Corporation | $22.85 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092313107 | CMS |
| Boston Scientific Corporation | $21.60 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092313105 | CMS |
| Gilead Sciences, Inc. | $124.02 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133644204 | CMS |
| Medtronic, Inc. | $18.21 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116867574 | CMS |
| Medtronic, Inc. | $82.25 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116867576 | CMS |
| Medtronic, Inc. | $36.76 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116867578 | CMS |
| Medtronic, Inc. | $29.30 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116867580 | CMS |
| Medtronic, Inc. | $34.47 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116867582 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.43 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137523571 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.